- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Juliette Petit: How Nurses Can Prevent Nocebo Effect in Biosimilar Switching
Juliette Petit, MD, a French rheumatologist, talks about her recent study showing that nurses can help curb patient fears and prevent a possible nocebo effect when switching them to a biosimilar.
If you are aware of the placebo effect, you may have heard of its opposite relative, the nocebo effect, where instead of positive thinking leading to an improvement in health, patient fears about drug quality may result in little or no effect from therapy. The nocebo effect is a common concern in the biosimilar space, where patients often doubt whether biosimilars are clinically similar to reference products.
A recent study on the nocebo effect in biosimilar use demonstrated that nurses may be best able to boost patient confidence in biosimilars and improve retention rates. The authors noted that because nurses are usually the first point of contact for patients in the health care system, they can be effective advocates at facilitating switching and biosimilar acceptance.
We sat down with Juliette Petit, MD, a rheumatologist at Saint-Antoine Hospital at Sorbonne University in Paris, France, and one of the study’s co-authors to discuss some of the major points in her study what it could mean for the future of biosimilar uptake.
Learn more about Dr Petit’s study.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
July 31st 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Policy Roundup for March 2023—Podcast Edition
July 31st 2025On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
July 31st 2025On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
